Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulfadoxine-pyrimethamine + mefloquine
- Development stage
- Unknown
- Lead developer
- Drugs for Neglected Diseases initiative
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sulfadoxine-pyrimethamine + mefloquine (Fansimef) is a fixed-dose combination antimalarial medication that combines three active ingredients: mefloquine, sulfadoxine, and pyrimethamine. This combination works by targeting multiple stages of the malaria parasite's lifecycle. Sulfadoxine inhibits dihydropteroate synthase (DHPS) and pyrimethamine inhibits dihydrofolate reductase (DHFR), both enzymes in the folate biosynthesis pathway of Plasmodium species. Mefloquine adds another mechanism of action to enhance efficacy against resistant strains. The combination was developed to treat chloroquine-resistant Plasmodium falciparum malaria.
- Brand names
- Fansimef
02
Targets
DHPS (Dihydropteroate synthase)DHFR (Dihydrofolate reductase)Heme
Beyond the preview
Go deeper on sulfadoxine-pyrimethamine + mefloquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulfadoxine-pyrimethamine + mefloquine.